AI-generated compounds hit specific cell types and outperform conventional screening

The classical drug discovery paradigm begins with a known molecular target: a protein whose modulation is expected to reverse the course of a disease. However, in many pathologies, such a target does not always exist or is not sufficiently characterized.

This report comes from Phys.org. The story centres on AI-generated compounds hit specific cell types and outperform conventional screening. Full coverage and background context is available at the original source. Readers seeking more detail on this developing topic are encouraged to follow updates from Phys.org and related outlets covering this beat.